Summary
Boston Scientific Corporation (BSX) announced a significant expansion of its stock repurchase program and a strengthening of its Board of Directors. The company's Board has approved an additional $4.0 billion authorization for common stock repurchases, bringing the total authorized amount to $5.0 billion, with the full amount remaining available. This move signals management's confidence in the company's financial position and its commitment to returning value to shareholders. In addition to the capital allocation update, the Board has been expanded to twelve directors with the appointment of two new independent directors, Catherine R. Smith and Christophe P. Weber. Both new directors bring valuable experience and will serve on key Board committees, including Audit, Nominating and Governance, Executive Compensation and Human Resources, and Risk, Science and Technology. These appointments are effective immediately, with committee assignments commencing February 23, 2026, and they will receive standard non-employee director compensation.
Key Highlights
- 1Board of Directors expanded from ten to twelve members.
- 2Catherine R. Smith and Christophe P. Weber appointed as new independent directors.
- 3New directors appointed to key committees: Audit, Nominating and Governance, Executive Compensation, and Risk, Science and Technology.
- 4Company authorized to repurchase up to an additional $4.0 billion of common stock.
- 5Total stock repurchase authorization increased to $5.0 billion, with the full amount remaining available.
- 6New directors to receive standard non-employee director compensation, including cash retainers and equity awards.
- 7Indemnification agreements to be entered into with new directors.